gsk1120212

Langerhans Cell Histiocytosis (LCH)

Cancer Research UKPhase 2/3Active

B

56/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 41/ 100
Competitive Position: 95/ 100

Competitive context

22 Active assets in the Langerhans Cell Histiocytosis (LCH) cohort.

Asset / Sponsor	Phase	Rating
Busulphan M.D. Anderson Cancer Center	Phase 2	B
Fludarabine M.D. Anderson Cancer Center	Phase 2	B
Evomela M.D. Anderson Cancer Center	Phase 2	B
Cyclophosphamide M.D. Anderson Cancer Center	Phase 2	B
Clofarabine M.D. Anderson Cancer Center	Phase 2	B

View all 28 →

Same molecule, other indications

gsk1120212 is also rated in:

anaplastic pleomorphic xanthoastrocytomaDormant

BB

Indicative ·

69 / 100

Glioma, High GradeDormant

BB

Indicative ·

69 / 100

anaplastic oligodendrogliomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.